CSTL Live signals | Maximize Profits with Getagraph.com

SELL 159243 min ago

@ $23.12

Issued: 13 Feb 2024 @ 12:40

Return: 0.61%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -2.45 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers...

Stats
Today's Volume	194 323
Average Volume	235 180
Market Cap	642.14M
EPS	$0 ( 2024-05-02 )
Next earnings date	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.58
ATR14	$0.0260 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-25	Bradbury Daniel	Buy	8 636	Common Stock
2024-05-25	Bradbury Daniel	Sell	8 636	Restricted Stock Units
2024-05-25	Caple Kim	Buy	8 636	Common Stock
2024-05-25	Caple Kim	Sell	8 636	Restricted Stock Units
2024-05-25	Cole G Bradley	Buy	8 636	Common Stock

INSIDER POWER
39.99
Last 99 transactions
Buy: 423 355 \| Sell: 177 274

Volume Correlation

Long: -0.17 (neutral)

Short: -0.01 (neutral)

Signal:(26.981) Neutral

Castle Biosciences Inc Correlation

10 Most Positive Correlations
OZEM	1
NEWZ	0.823

10 Most Negative Correlations
BKHA	-0.89
MNDR	-0.862
GTAPX	-0.83
INDH	-0.807
AGAQX	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Castle Biosciences Inc Correlation - Currency/Commodity

-0.55
( weak negative )

-0.13
( neutral )

0.00
( neutral )

-0.86
( strong negative )

-0.07
( neutral )

Castle Biosciences Inc Financials

Annual	2023
Revenue:	$219.79M
Gross Profit:	$164.23M (74.72 %)
EPS:	$-2.14

FY	2023
Revenue:	$219.79M
Gross Profit:	$164.23M (74.72 %)
EPS:	$-2.14

FY	2022
Revenue:	$137.04M
Gross Profit:	$105.03M (76.64 %)
EPS:	$-2.58

FY	2021
Revenue:	$94.09M
Gross Profit:	$78.26M (83.18 %)
EPS:	$-1.237

Financial Reports:

No articles found.

Castle Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Castle Biosciences Inc

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.